Table 3:

Qualitative assessment of patients with brain tumors: intraindividual comparison of 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate^{^a}

Diagnostic Information End Point	Reader	Gadobenate Preferred	No Difference	Gadoterate Preferred	Significance (P Value)^{^b}	3-Reader Agreement κ Value (% Agreement)
Global diagnostic preference	1	14 (14.6%)	75 (78.1%)	7 (7.3%)	.13	0.505 (63.4%)
	2	18 (19.2%)	56 (59.6%)	20 (21.3%)	.75
	3	15 (15.8%)	63 (66.3%)	17 (17.9%)	.73
Lesion-border delineation	1	11 (11.4%)	76 (79.2%)	9 (9.4%)	.824	0.493 (71.0%)
	2	12 (12.8%)	66 (70.2%)	16 (17.0%)	.46
	3	8 (8.4%)	77 (81.1%)	10 (10.5%)	.815
Definition of disease extent	1	6 (6.3%)	84 (87.5%)	6 (6.3%)	1.00	0.443 (79.6%)
	2	5 (5.3%)	83 (88.3%)	6 (6.4%)	1.00
	3	7 (7.4%)	80 (84.2%)	8 (8.4%)	1.00
Visualization of lesion internal morphology	1	4 (4.2%)	88 (91.7%)	4 (4.2%)	1.00	0.459 (84.9%)
	2	3 (3.2%)	87 (92.6%)	4 (4.3%)	1.00
	3	5 (5.3%)	82 (86.3%)	8 (8.4%)	.581
Lesion contrast enhancement	1	10 (10.4%)	77 (80.2%)	9 (9.4%)	1.00	0.531 (66.7%)
	2	18 (19.2%)	56 (59.6%)	20 (21.3%)	.75
	3	14 (14.7%)	64 (67.4%)	17 (17.9%)	.598

↵a Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n = 96 for reader 1, n = 94 for reader 2, and n = 95 for reader 3. Numbers in parentheses, except where noted, represent proportions of patients.
↵b Wilcoxon signed rank test.